Repudio AB is a Swedish biotech company founded in 2025, developing AdGalactica (Adf35(OGN)) — a first-in-class immunostimulatory adenoviral vector for treatment-resistant solid tumors.
AdGalactica is built on the immunology of xenotransplantation. Pig organ xenografts are rejected hyperacutely by the human immune system because of α-gal epitopes; AdGalactica reproduces that mechanism inside the tumor. The vector enters tumor cells via CD46, replicates selectively in pRb-dysregulated cells, and expresses two transgenes: GGTA1, which flags the tumor with α-gal epitopes, and H. pylori NAP, which turns an immunologically “cold” tumor “hot” and activates adaptive immunity. The result is intended to be systemic rejection of malignant cells with a mild tolerability profile.
AdGalactica is an off-the-shelf product requiring no personalisation, and is being developed for all solid tumors, starting with ovarian and pancreatic cancer. Two Phase 1 studies are underway in Oslo and Uppsala. Repudio is an incubator company at SmiLe Venture Hub.